Envoy Medical Inc., a Minnesota‑based developer of implantable hearing devices, said it received a Canadian patent (No. 3,130,978) covering an implantable cochlear system with integrated components and lead characterization, and a Hong Kong patent (No. HK40108431) covering a system and method for compensating variability in a middle‑ear sensor. The two grants bring the company’s worldwide patent portfolio to 97 issued patents, comprising 40 U.S. patents and 57 foreign patents, with an additional 35 applications pending – 26 abroad and nine in the United States.
The filings support Envoy’s two flagship products. The Esteem active middle‑ear implant has been commercially available in the United States since 2010. The Acclaim cochlear implant, currently under investigation, received FDA Breakthrough Device Designation in 2019 and is being evaluated in a U.S. pivotal clinical trial.
Chief Executive Officer Brent Lucas said the company differentiates itself by offering fully implanted hearing solutions that use the natural ear to capture sound, eliminating the need for external or sub‑dermal microphones.
The patents were issued by the Canadian Patent Office and the Hong Kong Patent Office, while the FDA remains the regulatory authority overseeing the Acclaim device’s clinical development.
